Inhibikase Therapeutics, Inc. (IKT) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $132.03K; Additional Paid in Capital, Common StockUSD $331.92M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-72.75K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $132.03K; Additional Paid in Capital, Common StockUSD $326.58M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-26.29K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $131.69K; Additional Paid in Capital, Common StockUSD $315.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $21.80K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $74.81K; Additional Paid in Capital, Common StockUSD $202.77M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.19K.
Inhibikase Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Value USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $132.03K | $331.92M | $-72.75K | $-178.65M | $153.33M | 3 month · $5.35M | (m) |
| 2026-03-31 | $0.00 | $132.03K | $326.58M | $-26.29K | $-159.06M | $167.62M | 3 month · $5.56M | (m) |
| 2025-12-31 | $0.00 | $131.69K | $315.43M | $21.80K | $-142.68M | $172.90M | 12 month · $15.31M | (m) |
| 2025-09-30 | $0.00 | $74.81K | $202.77M | $-4.19K | $-129.95M | $72.90M | 3 month · $4.53M | (m) |
| 2025-06-30 | $0.00 | $74.52K | $198.00M | $-2.94K | $-118.01M | $80.05M | 3 month · $4.21M | (m) |
| 2025-03-31 | $0.00 | $74.34K | $193.76M | $-967.00 | $-108.10M | $85.73M | 3 month · $2.04M | (m) |
| 2024-12-31 | $0.00 | $69.36K | $189.25M | $-37.25K | $-94.42M | $94.87M | 12 month · $8.14M | (m) |
| 2024-09-30 | $0.00 | $7.46K | $81.75M | $1.75K | $-82.29M | $-530.59K | 3 month · $148.02K | (m) |
| 2024-06-30 | $0.00 | $7.22K | $81.60M | $-1.02K | $-76.51M | $5.10M | 3 month · $30.70K | (m) |
| 2024-03-31 | $0.00 | $6.48K | $78.32M | $-1.80K | $-71.55M | $6.78M | 3 month · $53.43K | (m) |
| 2023-12-31 | $0.00 | $6.19K | $77.87M | $877.00 | $-66.90M | $10.98M | 12 month · $500.15K | (m) |
| 2023-09-30 | $0.00 | $5.36K | $77.74M | $-143.00 | $-62.72M | $15.02M | 3 month · $129.78K | (m) |
| 2023-06-30 | $0.00 | $5.29K | $77.59M | $-1.71K | $-58.13M | $19.46M | 3 month · $124.84K | (m) |
| 2023-05-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $195.98K |
| 2023-03-31 | $0.00 | $31.06K | $77.47M | $165.82K | $-52.35M | $25.28M | 3 month · $123.27K | (m) |
| 2022-12-31 | $0.00 | $4.22K | $68.80M | $104.72K | $-47.87M | $21.04M | 12 month · $458.15K | (m) |
| 2022-11-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $300.39K |
| 2022-09-30 | $0.00 | $25.23K | $68.68M | $26.83K | $-43.59M | $25.14M | 3 month · $101.79K | (m) |
| 2022-08-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $314.23K |
| 2022-06-30 | (m) | $25.23K | $68.58M | (m) | $-39.10M | $29.50M | 3 month · $132.77K | (m) |
| 2022-05-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $314.23K |
| 2022-03-31 | (m) | $25.23K | $68.44M | (m) | $-34.46M | $34.01M | 3 month · $123.23K | (m) |
| 2022-03-14 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $385.89K |
| 2021-12-31 | $0.00 | $25.16K | $68.21M | $0.00 | $-29.82M | $38.42M | 12 month · $1.53M | (m) |
| 2021-10-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $519.81K |
| 2021-09-30 | (m) | $25.16K | $67.91M | (m) | $-24.78M | $43.16M | 3 month · $352.42K | (m) |
| 2021-06-30 | (m) | $25.13K | $67.33M | (m) | $-20.30M | $47.05M | 3 month · $322.48K | (m) |
| 2021-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $772.42K |
| 2021-03-31 | (m) | $10.06K | $25.70M | (m) | $-17.67M | $8.04M | 3 month · $591.12K | (m) |
| 2020-12-31 | $0.00 | $10.05K | $24.81M | (m) | $15.03M | $9.78M | 12 month · $573.70K | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-5.13M | 3 month · $139.76K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-4.83M | 3 month · $139.76K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-4.70M | 3 month · $139.76K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-4.49M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |